# National Lipid Association > Mediated Wiki article. Canonical URL: https://mediated.wiki/source/National_Lipid_Association > Markdown URL: https://mediated.wiki/source/National_Lipid_Association.md > Source: https://en.wikipedia.org/wiki/National_Lipid_Association > Source revision: 1198768573 > License: Creative Commons Attribution-ShareAlike 4.0 International (https://creativecommons.org/licenses/by-sa/4.0/) American medical society The **National Lipid Association** (NLA) is an American non-profit multidisciplinary medical society that aims to enhance the practice of lipid management in [clinical medicine](/source/Clinical_medicine). The NLA focuses on the prevention of [cardiovascular disease](/source/Cardiovascular_disease) and other lipid-related disorders.[1] ## Overview The National Lipid Association was formed in 1997 and has over 2,000 members.[2][3] It provides medical education for healthcare professionals and physicians to advance knowledge and certification in clinical [lipidology](/source/Lipidology).[2] Joseph Saseen is the current president of NLA.[4][5] In 2014, the NLA proposed a working definition of [statin](/source/Statin) intolerance and made general recommendations for health professionals.[6][7] The NLA have stated that by 2012, a wealth of evidence including numerous clinical trials examined by the Cholesterol Treatment Trialists' Collaboration has confirmed the [lipid hypothesis](/source/Lipid_hypothesis).[8] The NLA publishes the *[Journal of Clinical Lipidology](/source/Journal_of_Clinical_Lipidology)*.[9] ## Scientific statements In 2019, the NLA's Nutrition and Lifestyle Task Force published a scientific statement based on a comprehensive review of recent clinical evidence on the effects of low and very-[low-carbohydrate diets](/source/Low-carbohydrate_diet) on the management of body weight and other cardiometabolic risk factors.[10][11] The statement concluded that low and very-low-carbohydrate die are not superior to other dietary approaches for weight loss and are difficult to maintain in the long term.[10][11] In 2021, the NLA published a scientific statement on lipid measurements in the management of cardiovascular diseases.[12] In 2022, the NLA published a scientific statement on statin intolerance, updating the definition which now classifies statin intolerance as either partial or complete.[13] The 2022 statement recommends different strategies to help patients stay on statin medications, and alternative medications to those who cannot tolerate statins.[1][14] ## Selected publications - Cheeley MK, Saseen JJ, Agarwala A, Ravilla S, Ciffone N, Jacobson TA, Dixon DL, Maki KC (2022). ["NLA scientific statement on statin intolerance: a new definition and key considerations for ASCVD risk reduction in the statin intolerant patient"](https://www.lipidjournal.com/article/S1933-2874(22)00167-2/fulltext). *J Clin Lipidol*. **16** (4): 361–375. [doi](/source/Doi_(identifier)):[10.1016/j.jacl.2022.05.068](https://doi.org/10.1016%2Fj.jacl.2022.05.068). [PMID](/source/PMID_(identifier)) [35718660](https://pubmed.ncbi.nlm.nih.gov/35718660). [S2CID](/source/S2CID_(identifier)) [249868408](https://api.semanticscholar.org/CorpusID:249868408).{{[cite journal](https://en.wikipedia.org/wiki/Template:Cite_journal)}}: CS1 maint: multiple names: authors list ([link](https://en.wikipedia.org/wiki/Category:CS1_maint:_multiple_names:_authors_list)) ## References 1. ^ [***a***](#cite_ref-Statement_1-0) [***b***](#cite_ref-Statement_1-1) ["Saseen Co-Authors National Lipid Association Official Scientific Statement on Statin Intolerance"](https://news.cuanschutz.edu/pharmacy/saseen-co-authors-national-lipid-association-official-scientific-statement-on-statin-intolerance). news.cuanschutz.edu. Retrieved 9 January 2023. 1. ^ [***a***](#cite_ref-Who_2-0) [***b***](#cite_ref-Who_2-1) ["Who We Are"](https://www.lipid.org/about). lipid.org. Retrieved 9 January 2023. 1. **[^](#cite_ref-3)** ["USA – National Lipid Association (NLA)"](https://www.athero.org/about-ias/member-societies/usa-national-lipid-association-nla/). athero.org. Retrieved 9 January 2023. 1. **[^](#cite_ref-4)** ["The NLA Welcomes New Leadership"](https://www.lipid.org/nla/nla-welcomes-new-leadership). lipid.org. Retrieved 9 January 2023. 1. **[^](#cite_ref-5)** ["Professor Joseph Saseen named president of National Lipid Association"](https://news.cuanschutz.edu/pharmacy/in-the-news/professor-joe-saseen-named-president-of-national-lipid-association). news.cuanschutz.edu. Retrieved 9 January 2023. 1. **[^](#cite_ref-6)** Guyton JR, Bays HE, Grundy SM, Jacobson TA (2014). ["The National Lipid Association Statin Intolerance Panel. An assessment by the Statin Intolerance Panel: 2014 update"](https://doi.org/10.1016%2Fj.jacl.2014.03.002). *J Clin Lipidol*. **8** (3): 72–81. [doi](/source/Doi_(identifier)):[10.1016/j.jacl.2014.03.002](https://doi.org/10.1016%2Fj.jacl.2014.03.002). [PMID](/source/PMID_(identifier)) [24793444](https://pubmed.ncbi.nlm.nih.gov/24793444).{{[cite journal](https://en.wikipedia.org/wiki/Template:Cite_journal)}}: CS1 maint: multiple names: authors list ([link](https://en.wikipedia.org/wiki/Category:CS1_maint:_multiple_names:_authors_list)) 1. **[^](#cite_ref-7)** ["The National Lipid Association Addresses the Safety of Statins and Provides Recommendations to Clinicians and Patients"](https://www.businesswire.com/news/home/20140502005025/en/The-National-Lipid-Association-Addresses-the-Safety-of-Statins-and-Provides-Recommendations-to-Clinicians-and-Patients). businesswire.com. Retrieved 9 January 2023. 1. **[^](#cite_ref-8)** ["The Lipid Hypothesis"](https://www.lipid.org/lipid-spin/summer-2022/lipid-hypothesis). lipid.org. Retrieved 22 January 2024. 1. **[^](#cite_ref-9)** ["Journal of Clinical Lipidology"](https://www.sciencedirect.com/journal/journal-of-clinical-lipidology). sciencedirect.com. Retrieved 9 January 2023. 1. ^ [***a***](#cite_ref-Kirkpatrick_2019_10-0) [***b***](#cite_ref-Kirkpatrick_2019_10-1) Kirkpatrick CF, Bolick JP, Kris-Etherton PM, et al. (2019). ["Review of current evidence and clinical recommendations on the effects of low-carbohydrate and very-low-carbohydrate (including ketogenic) diets for the management of body weight and other cardiometabolic risk factors: A scientific statement from the National Lipid Association Nutrition and Lifestyle Task Force"](https://www.lipidjournal.com/article/S1933-2874(19)30267-3/fulltext). *Journal of Clinical Lipidology*. **13** (5): 689–711.e1. [doi](/source/Doi_(identifier)):[10.1016/j.jacl.2019.08.003](https://doi.org/10.1016%2Fj.jacl.2019.08.003). [PMID](/source/PMID_(identifier)) [31611148](https://pubmed.ncbi.nlm.nih.gov/31611148). [S2CID](/source/S2CID_(identifier)) [203514787](https://api.semanticscholar.org/CorpusID:203514787). 1. ^ [***a***](#cite_ref-Quackwatch_11-0) [***b***](#cite_ref-Quackwatch_11-1) ["Low-carbohydrate diet claims scrutinized"](https://quackwatch.org/ncahf/digest20/20-01/). quackwatch.org. Retrieved 9 January 2023. 1. **[^](#cite_ref-12)** ["Utilization of Clinical Testing in the Setting of Dyslipidemia"](https://www.acc.org/latest-in-cardiology/articles/2021/11/22/13/11/utilization-of-clinical-testing-in-the-setting-of-dyslipidemia). acc.org. Retrieved 9 January 2023. 1. **[^](#cite_ref-13)** ["NLA 2022 Definition of Statin Intolerance"](https://www.acc.org/latest-in-cardiology/articles/2022/08/08/12/27/nla-2022-definition-of-statin-intolerance). acc.org. Retrieved 9 January 2023. 1. **[^](#cite_ref-14)** ["New National Lipid Association Statement on Statin Intolerance"](https://archive.today/20220623115934/https://www.medscape.com/viewarticle/975674). medscape.com. Retrieved 9 January 2023. ## External links - [National Lipid Association](https://www.lipid.org/) --- Adapted from the Wikipedia article [National Lipid Association](https://en.wikipedia.org/wiki/National_Lipid_Association) by Wikipedia contributors ([contributor history](https://en.wikipedia.org/wiki/National_Lipid_Association?action=history)). Available under [Creative Commons Attribution-ShareAlike 4.0 International](https://creativecommons.org/licenses/by-sa/4.0/). Changes may have been made.